ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $11,379 | $32,596 | $1,953 | $1,150 |
| - Cash | $527,978 | $72,086 | $1,612 | $1,531 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$516,599 | -$39,490 | $341 | -$381 |
| Revenue | $0 | $0 | $0 | $26 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $13 |
| % Margin | – | – | – | 50% |
| EBITDA | -$20,752,130 | -$2,081 | -$2,257 | -$1,287 |
| % Margin | – | – | – | -4,933.7% |
| Net Income | -$19,805,559 | -$2,211 | -$2,257 | -$1,422 |
| % Margin | – | – | – | -5,451.7% |
| EPS Diluted | -2.56 | -0.46 | -0.73 | -1.31 |
| % Growth | -456.5% | 37% | 44.3% | – |
| Operating Cash Flow | -$1,406,912 | -$1,521,728 | -$1,772,052 | -$1,225 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,406,912 | -$1,521,728 | -$1,772,052 | -$1,225 |